MORPHOSYS AG O.N. news, videos and press releases - Page 6
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- DGAP-News: MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
- MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
- DGAP-News: MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
- MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
- DGAP-News: MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
- MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
- DGAP-News: MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- DGAP-News: MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
- MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
- DGAP-News: MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
- MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
- DGAP-News: MorphoSys to Acquire Constellation Pharmaceuticals
- DGAP-Adhoc: MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
- MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
- DGAP-News: MorphoSys To Participate in UBS Global Healthcare Conference
- MorphoSys To Participate in UBS Global Healthcare Conference
- DGAP-News: MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting
- MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting
- DGAP-News: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
- DGAP-News: MorphoSys AG Reports First Quarter 2021 Results
- MorphoSys AG Reports First Quarter 2021 Results
- DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021
- DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021
- DGAP-News: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory FL or MZL
- DGAP-News: MorphoSys AG Presents Results for Full Year 2020
- MorphoSys AG Presents Results for Full Year 2020
- DGAP-News: Invitation to MorphoSys' Full Year Results 2020 Conference Call on March 16, 2021
- Invitation to MorphoSys' Full Year Results 2020 Conference Call on March 16, 2021
- DGAP-News: MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease
